SEARCH - DEVELOP - INNOVATE
scroll

Thanks to a deep understanding of metabolic disorders and physiopathology, LNC Therapeutics develops gut microbiota directed drugs to tackle obesity and its associated cardiometabolic diseases

LNC LNC Therapeutics is working on the first gut microbiota directed drugs initiated by a medical nutrition product clinical outcomes

Our solutions for metabolic diseases

STABLOR
Medical Nutrition Product
TEMYS PROJECT
Gut microbiota directed drugs
Who benefits

Patients

Public Health

Pharmaceutical groups

Human gut microbiome is a revolutionary field presenting numerous promising opportunities in obesity management

More
about us

From the creation of LNC Therapeutics, the founders shared the same vision: to address the issue of obesity by acting on its fundamental causes

Learn more
Publications

In order to be on the cutting edge of scientific research and innovation, we select and analyse key scientific publications and materials

Discover our selection

Find out more
LNC Therapeutics raises € 6,5...
Cardiometabolic research specialist announces Sandrine Claus appointment as Chief Scientific Officer...
The strong protective role of...
Variation in the human fecal microbiota has previously been associated with body mass index (BMI)....
C.minuta is the species related...
Host genetics and the gut microbiome can both influence metabolic phenotypes. Here, Goodrich et al....
What is the link between...
Evidence suggests the gut microbiome is involved in the development of cardiovascular disease (CVD),...